Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

被引：15
作者：
Rhee, Rennie L. [1 ]
Gabler, Nicole B. [1 ]
Praestgaard, Amy [1 ]
Merkel, Peter A. [1 ]
Kawut, Steven M. [1 ]
机构：
[1] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷 / 09期
关键词：
D O I：
10.1002/art.39220
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ObjectivePatients with connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH) have a poorer prognosis compared to those with idiopathic PAH, but little is known about the differences in treatment-related adverse events (AEs) and serious adverse events (SAEs) between these groups. This study was undertaken to characterize these differences. MethodsIndividual patient-level data from 10 randomized controlled trials of therapies for PAH were obtained from the US Food and Drug Administration. Patients diagnosed as having either CTD-associated PAH or idiopathic PAH were included. A treatment-by-diagnosis interaction term was used to examine whether the effect of treatment on occurrence of AEs differed between patients with CTD-associated PAH and those with idiopathic PAH. Studies were pooled using fixed-effect models. ResultsThe study sample included 2,370 participants: 716 with CTD-associated PAH and 1,654 with idiopathic PAH. In the active treatment group compared to the placebo group, the risk of AEs was higher among patients with CTD-associated PAH than among those with idiopathic PAH (odds ratio [OR] 1.57, 95% confidence interval [95% CI] 1.00-2.47 versus OR 0.94, 95% CI 0.69-1.26; P for interaction = 0.061), but there was no difference in the risk of SAEs in analyses adjusted for age, race, sex, hemodynamic findings, and laboratory values. Despite the higher occurrence of AEs in patients with CTD-associated PAH assigned to active therapy compared to those receiving placebo, the risk of drug discontinuation due to an AE was similar to that in patients with idiopathic PAH assigned to active therapy (P for interaction = 0.27). ConclusionPatients with CTD-associated PAH experienced more treatment-related AEs compared to those with idiopathic PAH in therapeutic clinical trials. These findings suggest that the overall benefit of advanced therapies for PAH may be attenuated by the greater frequency of AEs.
引用
收藏
页码：2457 / 2465
页数：9
相关论文
共 56 条
  • [31] Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Et al., Sildenafil citrate therapy for pulmonary arterial hypertension, N Engl J Med, 353, pp. 2148-2157, (2005)
  • [32] Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., Et al., Inhaled iloprost for severe pulmonary hypertension, N Engl J Med, 347, pp. 322-329, (2002)
  • [33] Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., Et al., Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial, Am J Respir Crit Care Med, 165, pp. 800-804, (2002)
  • [34] Pulido T., Adzerikho I., Channick R.N., Delcroix M., Galie N., Ghofrani H.A., Et al., Macitentan and morbidity and mortality in pulmonary arterial hypertension, N Engl J Med, 369, pp. 809-818, (2013)
  • [35] Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., Et al., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study, Lancet, 358, pp. 1119-1123, (2001)
  • [36] Olschewski H., Hoeper M.M., Behr J., Ewert R., Meyer A., Borst M.M., Et al., Long-term therapy with inhaled iloprost in patients with pulmonary hypertension, Respir Med, 104, pp. 731-740, (2010)
  • [37] Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., Et al., Tadalafil therapy for pulmonary arterial hypertension, Circulation, 119, pp. 2894-2903, (2009)
  • [38] McLaughlin V.V., Benza R.L., Rubin L.J., Channick R.N., Voswinckel R., Tapson V.F., Et al., Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial, J Am Coll Cardiol, 55, pp. 1915-1922, (2010)
  • [39] Tapson V.F., Torres F., Kermeen F., Keogh A.M., Allen R.P., Frantz R.P., Et al., Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial, Chest, 42, pp. 1383-1390, (2012)
  • [40] Jing Z.C., Parikh K., Pulido T., Jerjes-Sanchez C., White R.J., Allen R., Et al., Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial, Circulation, 127, pp. 624-633, (2013)
123456